UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
March 5, 2004
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
Registrant issued on March 5, 2004 a press release announcing
completion of the manufacture of validation batches for a once-a-day product
which treats allergies and the symptoms of allergies. The product was developed
for an undisclosed U.S. pharmaceutical company.
A copy of Registrant's press release is attached as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1. Press Release, dated March 5, 2004
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 5, 2004
ELITE PHARMACEUTICALS, INC.
By: /s/ BERNARD BERK
----------------------------
Name: Bernard Berk
Title: Chief Executive Officer